The February 2027 Docket: LL-37, GHK-Cu, Dihexa, Melanotan II and PEG-MGF Under Review

July was not the end of the process. It was the first of at least two meetings.

The FDA has confirmed that the Pharmacy Compounding Advisory Committee will convene again before the end of February 2027 to consider five more peptides. As of today the exact date has not been posted.

The five are cathelicidin LL-37, GHK-Cu, dihexa acetate, Melanotan II, and PEG-MGF. Between them they cover immune signaling, dermatology, cognition, pigmentation and muscle growth — a considerably wider spread than the July slate, and one that reaches a much broader consumer audience.

The five, and why each is on the list

GHK-Cu

The copper tripeptide is the commercially significant one, because it already exists in mainstream retail as a cosmetic ingredient while simultaneously being a federal regulatory subject.

The distinction is route. Non-injectable GHK-Cu sits in Category 1 — the enforcement-discretion bucket — which is why topical copper-peptide serums occupy different ground from everything else discussed here. Injectable GHK-Cu was among the twelve removed from Category 2 in April 2026 and is what goes before the committee.

Same molecule, two regulatory realities, separated entirely by how it is delivered. That is a nuance the skincare market has almost entirely failed to communicate.

Cathelicidin LL-37

An antimicrobial peptide involved in innate immune defense, studied in laboratory and animal models for antimicrobial activity, immune signaling, wound repair and biofilm disruption.

The FDA has previously identified a demanding set of concerns: limited human safety information, potential immunogenicity, reproductive findings in nonclinical research, and the possibility of tumor-promoting activity in certain tissues. That last item is not a small objection, and it makes LL-37 arguably the hardest case on the February slate.

Melanotan II

A melanocortin receptor agonist marketed for tanning. It has the longest consumer-harm record of anything in this group, with published reports linking use to changes in existing moles and to broader dermatologic concerns — which sits awkwardly alongside a product whose entire premise is pigmentation.

Of the five, this is the one where the gap between marketing enthusiasm and clinical caution is widest.

Dihexa acetate

An angiotensin IV analog investigated for neurotrophic activity, with essentially all of the interesting work in preclinical models. Human data is close to nonexistent. It is a compound with a genuinely interesting proposed mechanism and almost no clinical evidence base — a combination the committee has already shown itself willing to vote on either way.

PEG-MGF

Pegylated mechano growth factor, an IGF-1 splice variant modified for a longer half-life, associated with muscle repair research. It carries the anabolic-agent baggage that tends to attract regulatory scrutiny beyond the compounding question, and it is banned in competitive sport.

Why these five were withdrawn and are now back

All five were among the twelve peptides removed from Category 2 in April 2026, following withdrawal of their nominations. Four of them — LL-37, dihexa, Melanotan II and PEG-MGF — had no active review pathway after that withdrawal. Scheduling them for the February meeting puts them back into formal consideration.

GHK-Cu is the exception, having been recategorized to Category 1 for non-injectable routes.

What July tells us about February

The July meeting produced a usable pattern.

FDA scientists opposed everything. All seven nominations drew a recommendation against inclusion from agency reviewers, citing insufficient safety data, insufficient efficacy data and inadequate characterization. There is no reason to expect a different posture in February, and LL-37's tumor-promotion concern is more serious than most of what was raised in July.

The committee overrode staff six times. If the panel's composition is unchanged, the base rate favors recommendation.

Narrow indications did better. Emideltide came in with three indications spanning addiction medicine and two sleep disorders, and it was the only rejection. Compounds nominated for a single, measurable use fared better. How the February five are framed may matter more than their underlying evidence.

Margins were tight throughout. The widest was three votes. Nothing about the July outcome suggests February is a formality.

The commercial stakes

GHK-Cu is the one with real market consequences. It is already sold at scale in cosmetic formulations under a regulatory framework that has nothing to do with compounding. A February recommendation on injectable GHK-Cu would not change topical products — but it would almost certainly be marketed as though it did.

Expect a wave of copy in early 2027 implying that a vote on injectable copper peptide validates a face serum. It would not. The two sit in different regulatory systems for different reasons, and the vote would concern neither cosmetic safety nor cosmetic efficacy.

What to watch for

The meeting date has not been posted. When it is, the FDA will publish briefing materials roughly two business days beforehand — those documents contain the agency's own position on each substance and are the most informative thing available before the vote. A public comment docket will open alongside the announcement.

The other thing to watch is whether the FDA acts on the July recommendations before February. If a proposed rule publishes in the interim, it establishes the template for how these substances get handled — and would tell you considerably more about February's practical significance than the vote itself.